CorMedix develops and sells DefenCath, a catheter lock solution for dialysis patients, plus hospital infection drugs and a heart medicine. It last closed at $4.67 on Nov 17, down 3.11% on the day. The average 12-month price target from 3 analysts is $13.33 (+185.5% from the last close), with a high of $15.00 and a low of $12.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $237K, the largest $237K.
Each firm's latest rating on CRMD in the past 90 days
Average 12-month target
$13.33
▲ 185.5% upside
Based on 3 analysts who set a price target on CRMD in the past 90 days. The average target is $13.33, with a high of $15.00 and a low of $12.00, compared with the last close of $4.67.
Low $12.00Avg $13.33High $15.00
Blue marker: last close $4.67
Highest target$15.00
Average target$13.33
Lowest target$12.00
Latest rating changes
OppenheimerTarget lowered
Nov 13Buy$15 → $13
RBC CapitalMaintained
Nov 10Buy$15
NeedhamMaintained
Nov 2Buy$12
OppenheimerInitiated
Sep 23Buy$15
Date
Firm
Action
Rating
Price target
Nov 13
Oppenheimer
Target lowered
Buy
$15 → $13
Nov 10
RBC Capital
Maintained
Buy
$15
Nov 2
Needham
Maintained
Buy
$12
Sep 23
Oppenheimer
Initiated
Buy
$15
Loading…
Technical Analysis
CRMD · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 32% below its 20 day and 51% below its 50 day average. It is 61% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 52 week low at $4.63, and the nearest resistance the Pivot at $4.72.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 8.9%/day
Key levels
$13.0252 week high+178.8%
$7.66Swing high (Aug 4)+64.0%
$7.55100 day average+61.7%
$7.53200 day average+61.2%
$7.0450 day average+50.7%
$6.1820 day average+32.3%
$4.81Pivot R1+3.0%
$4.72Pivot+1.1%
$4.67Last close
$4.6352 week low−0.9%
$4.58Pivot S1−1.9%
Indicators
RSI (14)
26.09
Oversold below 30
Oversold
MACD
-0.74
Below its signal line
Bearish
Stochastic
1.9
Near the bottom of its range
Oversold
ADX (14)
35.5
Trending down
Williams %R
-99.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-84.9
Oversold below −100, overbought above 100
Neutral
Rate of change
−16.0%
Change over 10 sessions
Bearish
ATR (14)
$0.41
Typical daily range, 8.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityNormal, 18.8%/day
Key levels
$13.0252 week high+178.8%
$7.66Swing high (Aug 4)+64.0%
$7.55100 day average+61.7%
$7.53200 day average+61.2%
$7.0450 day average+50.7%
$6.1820 day average+32.3%
$4.81Pivot R1+3.0%
$4.72Pivot+1.1%
$4.67Last close
$4.6352 week low−0.9%
$4.58Pivot S1−1.9%
Indicators
RSI (14)
28.72
Oversold below 30
Oversold
MACD
-0.76
Below its signal line
Bearish
Stochastic
2.3
Near the bottom of its range
Oversold
ADX (14)
15.0
No clear trend
Williams %R
-99.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-214.8
Oversold below −100, overbought above 100
Oversold
Rate of change
−40.4%
Change over 10 sessions
Bearish
ATR (14)
$0.88
Typical daily range, 18.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for CRMD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CRMD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CRMD usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CRMD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2010.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRMD is in one of them and how their past CRMD trades turned out.
CorMedix is a biopharmaceutical company based in Parsippany, New Jersey, that develops and sells drugs for serious medical conditions. Its main product is DefenCath, a catheter lock solution that helps reduce bloodstream infections in adult kidney failure patients who receive dialysis through a central venous catheter. Its customers are mainly outpatient dialysis clinics and hospitals. The company also sells a set of hospital-focused drugs for serious infections, including REZZAYO and VABOMERE, along with the heart drug TOPROL XL. These products are used in hospitals, emergency departments, outpatient clinics and home infusion care.